Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases

Completed · Phase 2 · Has a placebo group

Conditions studied: Diabetes Mellitus, Hypertension, Metabolic Disease, Obesity, Sleep Apnea Syndrome

In brief

Obesity is a condition affecting one-third off the U.S. population and is a major risk actor for the development of Type 2 diabetes, hyperlipidemia (increased levels of fat in the blood), hypertension (high blood pressure), and other disorders of the heart and lungs. Individuals with the onset of obesity during childhood or adolescence are at an increased risk of obesity-related, diseases, both during adolescence and later in adult life. African American girls and women are at an increased risk for obesity, and have substantial rates of obesity-related diseases and causes of death. Further, many African American adult women fail to respond to many of the therapeutic approaches used to treat obesity. At present there are no medical therapies proven effective for the correction of severe obesity in children or adolescents. One medication that may have a favorable risk-benefit ratio in pediatric populations is Orlistat (Xenical, Hoffmann LaRoche). Orlistat works by preventing the action of enzymes in the digestive process, interfering with the absorption of approximately 1/3 of the fat eaten in the diet. Xenical appears to be effective for reducing weight and obesity-associated diseases in obese adults. Researchers propose to determine the safety, tolerability, and efficacy of Xenical in 12-17 year old severely obese African American and Caucasian children and adolescents who have one or more obesity-related disease (hypertension, hyperlipidemia, sleep apnea, hepatic steatosis, insulin resistance, impaired glucose tolerance, or Type 2 diabetes).

Key facts

Study ID

NCT00001723

Run by

Jack Yanovski

People needed

200

Starts

1998-05-01

Expected to finish

2011-10-01

Last updated by the study team

2012-12-18

Who can join

Age: 12 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Volunteers will be excluded (and referred to non-experimental treatment programs) for the following reasons:
• Presence of renal, hepatic (other than obesity-related steatosis), gastrointestinal, most endocrinologic (e.g., Cushing syndrome), or pulmonary disorders (other than either asthma not requiring continuous medication or sleep apnea-related disorders);
• Adolescent girls who are pregnant, who are currently nursing an infant, or who are having unprotected intercourse;
• Individuals who have, or whose parent or guardians have, current substance abuse or a psychiatric disorder or other condition which, in the opinion of the investigators, would impede competence or compliance or possibly hinder completion of the study;
• Subjects who regularly use prescription medications unrelated to the complications of obesity. Oral contraceptive use will be permitted, provided the contraceptive has been used for at least two months before starting study medication. The use of over-the-counter and prescription medications will be reviewed on a case-by-case basis; depending on the medication, subjects who have continued to take prescription medication for at least 3 months prior to study entry may be eligible;
• Recent use (within six months) of anorexiant medications for the purpose of weight reduction;
• Inability to undergo MRI (e.g., volunteers with metal within their bodies including cardiac pacemakers, neural pacemakers, aneurysmal clips, shrapnel, ocular foreign bodies, cochlear implants, non-detachable electronic or electromechanical devices such as infusion pumps, nerve stimulators, bone growth stimulators, etc. that are contraindications).
• For pilot study participants, hypersensitivity or allergy to methylene blue. Individuals with documented G6PD deficiency will be excluded.
• INCLUSION CRITERIA: HEALTHY CONTROL CHILDREN AND ADOLESCENTS:
• Volunteers will qualify for inclusion if they meet the following criteria:
• Good general health.
• Age 12-17 years at study entry.
• Body mass index (BMI) for age above the 5th percentile and below 85th percentile, which is considered normal weight by CDC growth chart standards.
• For females with childbearing potential, a negative pregnancy test at initial evaluation.
• Race of all four grandparents self-identified as either all Caucasian or all African American.
• EXCLUSION CRITERIA: HEALTHY CONTROL CHILDREN AND ADOLESCENTS:
• Volunteers will be excluded for the following reasons:
• Presence of past or present medical problems which would impair performance during the exercise tests;
• Females who are pregnant, or who are currently nursing an infant;
• Individuals who have, or whose parent or guardian has, current substance abuse or a psychiatric disorder or other condition that in the opinion of the investigators would impede competence or possibly hinder completion of the study;
• Recent weight change of more than 3% of body weight in the past two months;
• Recent use (within six months) of anorexiant medications for the purpose of weight reduction;
• Physical impairments that would prevent completion of either the walk/run test or the cycle test.

Where it is running

• National Institutes of Health Clinical Center, 9000 Rockville Pike — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.